Invest In Psychedelic Therapy?
Psychedelic Therapy Clinics are popping up all over LA and Arizona. Some of them charge up to $2,000 for a full treatment... this is an emerging trend every investor should consider.
Tell Me More About Psychedelic Therapy

VRPX Insider Trading (Virpax Pharmaceuticals)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $716.00
Insider Selling (Last 12 Months): $0.00

Virpax Pharmaceuticals Insider Trading History Chart

Virpax Pharmaceuticals Share Price & Price History

▼ -0.06 (-1.54%)
As of 06/22/2021 01:25 PM ET
Days: 30 | 90 | 365
Is this Seattle Penny Pot Stock a Potential Blockbuster?
A small, rapidly expanding Seattle cannabis company is gaining attention from investors. Founded by two cannabis veterans, the company has increased sales 8-fold and is looking to double sales again in the next two years. Now selling for less than $1 per share, this is an opportunity to acquire thousands of shares – a potential windfall.
Get Free Report on #1 Cannabis Pick for 2021

Virpax Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/17/2021Thani JambulingamDirectorBuy100$7.16$716.00100View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Virpax Pharmaceuticals (NASDAQ:VRPX)

5.55% of Virpax Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Virpax Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/14/2021HN Saltoro Capital LP27,000$0.13M0.0%N/A0.546%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Virpax Pharmaceuticals, Inc., a preclinical stage biopharmaceutical company, develops and manufactures non-opioid and non-addictive pharmaceutical products using drug delivery systems for pain management. The company offers products, such as Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; Probudur (LBL100), long-acting bupivacaine liposomal gel for postoperative pain management; OSF200 for chronic osteoarthritis of the knee; and NES100 (Envelta), an exogenous enkephalin intranasal spray for acute and chronic pain. It also develops PES200 for the management of post-traumatic stress disorder; and MMS019 high-density molecular masking spray to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Read More on Virpax Pharmaceuticals

Today's Range

Now: $3.84

50 Day Range

MA: $4.24

52 Week Range

Now: $3.84


1,708 shs

Average Volume

252,829 shs

Market Capitalization

$19.05 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Virpax Pharmaceuticals?

Virpax Pharmaceuticals' top insider investors include:
  1. Thani Jambulingam (Director)

Who are the major institutional investors of Virpax Pharmaceuticals?

Virpax Pharmaceuticals' top institutional shareholders include:
  1. HN Saltoro Capital LP — 0.55%

Which institutional investors are buying Virpax Pharmaceuticals stock?

Within the previous quarter, VRPX stock was acquired by institutional investors including:
  1. HN Saltoro Capital LP
Peter Thiel Bets Big On "Mushroom Boom."
LSD and "Mushroom stocks" are being listed on the NASDAQ and a recent breakthrough makes top investors VERY excited about the coming "Mushroom Boom."
Click Here To Read The Full Story